All In Biotech

Drug Trial Radar · NCT03596866

A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Last checked: Nov 19, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 248 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

248

Actual

Start

Apr 19, 2019

Primary completion

Feb 27, 2024

Study completion Sep 18, 2024

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jul 24, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Brigatinib is a medicine that binds to the surface of tumor cells in some cancers and delivers a dose of chemotherapy directly to the tumor. In this study, participants will be people with non-small-cell lung cancer (NSCLC for short). The main aim of the study is to learn if brigatinib stops the tumors from growing, or if the tumors have shrunk or disappeared, compared to a medicine called alectinib. At the first visit, the study doctor will check who can take part. Participants who can take part will be picked for 1 of 2 treatments by chance: * Brigatinib tablets * Alectinib capsules All participants will take brigatinib or alectinib at about the same time every day. They will continue with treatment throughout the study unless their cancer gets worse, they have side effects from the treatment, they leave the study for certain reasons, or the study is stopped. After stopping treatment, participants will visit the study clinic for a check-up 30 days later.

Conditions

  • ALK+ Advanced NSCLC

Interventions

  • BrigatinibDrug

    Brigatinib Tablets.

  • AlectinibDrug

    Alectinib Capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1Time frame: Up to 33.8 months

Locations

114 sites in 20 countries. Site status is shown where the registry gives one.

  • The Oncology Institute of Hope and Innovation

    Whittier, California

  • University Cancer and Blood Center

    Athens, Georgia

  • New York Oncology Hematology - Albany Medical Center

    Albany, New York

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Sanatorio Duarte Quiros

    Córdoba, Argentina

  • Centro Oncologico Riojano Integral

    La Rioja, Argentina

  • Centro Para la Atencion Integral del Paciente Oncologico

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Klinikum Klagenfurt Am Worthersee

    Klagenfurt, Carinthia, Austria

  • Queen Elizabeth II Health Sciences Centre

    Halifax, Nova Scotia, Canada

  • Toronto University Health Network

    Toronto, Ontario, Canada

  • Centro de Investigacion Clinica Bradford Hill

    Recoleta, Santiago Metropolitan, Chile

  • Beijing Chest Hospital

    Beijing, Beijing Municipality, China

  • Peking Union Medical College Hospital - East

    Beijing, Beijing Municipality, China

  • Peking University Cancer Hospital/Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • The 307th Hospital of Chinese Peoples Liberation Army

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Affiliated Tumor Hospital of Harbin Medical University - The 3rd Affiliated Hospital of HMU

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Jilin Provincial Cancer Hospital (Changchun Cancer Hospital)

    Changchun, Jilin, China

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China

  • Chang Gung Memorial Hospital Linkou Branch

    Tianjin, Tianjin Municipality, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

  • The First Affiliated Hospital, Zhejiang University

    Hangzhou, Zhejiang, China

  • General Hospital Pula

    Pula, Croatia

  • Klinicki bolnicki centar Sestre milosrdnice

    Zagreb, Croatia

  • Klinika za Pulmologiju

    Zagreb, Croatia

  • Fudan University Shanghai Cancer Center

    Dubrovnik, Dubrovnik-Neretva County, Croatia

  • Opca bolnica Dubrovnik

    Dubrovnik, Dubrovnik-Neretva County, Croatia

  • Hopital Haut-Leveque

    Pessac, Aquitaine, France

  • Hopital Albert Michallon

    Grenoble, Auvergne-Rhône-Alpes, France

  • Centre Hospitalier Intercommunal de Creteil

    Créteil, Île-de-France Region, France

  • Fudan University Shanghai Cancer Center

    Créteil, Île-de-France Region, France

  • Hopital Foch

    Suresnes, Île-de-France Region, France

  • Gustave Roussy

    Villejuif, Île-de-France Region, France

  • Centre Hospitalier Universitaire de Toulouse- Hopital Larrey

    Toulouse, Midi-pyrenees, France

  • Centre Hospitalier Le Mans

    Le Mans, Pays de la Loire Region, France

  • Centre Hospitalier Intercommunal Toulon - La Seyne Sur Mer

    Toulon, Provence-Alpes-Côte d'Azur Region, France

  • Thoraxklinik Heidelberg

    Heidelberg, Baden-Wurttemberg, Germany

Showing 40 of 114 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.